IBRX270416C00014000
IBRX Apr 16 2027 14.00 Call
optionOPRA
InactiveOct 5, 2026
2.10USD+22.807%(+0.39)20Vol21OI
Loading…
Underlying
Underlying Price
$8.36
Type
Call
Strike
14
Expiration
Apr 16, 2027
DTE
178d
Moneyness
OTM
Intrinsic
$0.00
IBRX 14 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | $0.10 | +42.86% | 1 | 1 |
| Nov 6, 2026 | 17d | $0.22 | -56.00% | 100 | 145 |
| Nov 13, 2026 | 24d | $0.58 | +0.00% | 1 | 1 |
| Nov 20, 2026 | 31d | $0.30 | -11.76% | 40 | 2,285 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | $0.60 | +0.00% | 2 | 2 |
| Jan 15, 2027 | 87d | $1.00 | -16.67% | 10 | 3,110 |
| Mar 19, 2027 | 150d | $1.50 | -25.74% | 5 | 35 |
| Apr 16, 2027 | 178d | $2.10 | +22.81% | 20 | 21 |
| May 21, 2027 | 213d | — | — | 0 | 0 |
IBRX Nearby Strikes · Apr 16, 2027
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.